The Genetic Evolution of Melanoma from Precursor Lesions.

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. PLoS Med (2016) 1.48

The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci (2016) 1.36

The Genetic Evolution of Melanoma. N Engl J Med (2016) 1.20

Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) (2016) 0.93

The Genetic Evolution of Melanoma. N Engl J Med (2016) 0.91

The Genetic Evolution of Melanoma. N Engl J Med (2016) 0.90

Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res (2016) 0.90

The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget (2016) 0.89

Melanocortin 1 Receptor: Structure, Function, and Regulation. Front Genet (2016) 0.88

Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. J Invest Dermatol (2016) 0.80

Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proc Natl Acad Sci U S A (2016) 0.79

The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. Sci Data (2017) 0.79

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget (2016) 0.79

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications. Genes (Basel) (2016) 0.79

Pembrolizumab (Keytruda). Hum Vaccin Immunother (2016) 0.78

Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies. Oncotarget (2016) 0.77

Shorter telomere length in Europeans than in Africans due to polygenetic adaptation. Hum Mol Genet (2016) 0.77

Defining the genetics of melanoma progression. Lancet Oncol (2015) 0.77

Hepatic small vessel neoplasm, a rare infiltrative vascular neoplasm of uncertain malignant potential. Hum Pathol (2016) 0.77

Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77

Elastic-Fluid Model for DNA Damage and Mutation from Nuclear Fluid Segregation Due to Cell Migration. Biophys J (2017) 0.77

Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol (2016) 0.76

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76

Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention. Future Oncol (2016) 0.76

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Front Immunol (2017) 0.76

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med (2017) 0.75

Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma. Sci Rep (2017) 0.75

Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. Oncotarget (2016) 0.75

The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics (2017) 0.75

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. Int J Mol Sci (2017) 0.75

The Genetic Evolution of Melanoma. N Engl J Med (2016) 0.75

Optimized Prediction of Extreme Treatment Outcomes in Ovarian Cancer. Cancer Inform (2016) 0.75

Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia. Schizophr Bull (2016) 0.75

Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas. Mod Pathol (2017) 0.75

Epigenetic and genetic dissections of UV-induced global gene dysregulation in skin cells through multi-omics analyses. Sci Rep (2017) 0.75

p15 Expression Differentiates Nevus from Melanoma. Am J Pathol (2016) 0.75

Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. F1000Res (2016) 0.75

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue. Genome Med (2016) 0.75

Paracrine regulation of melanocyte genomic stability: a focus on nucleotide excision repair. Pigment Cell Melanoma Res (2017) 0.75

The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing. Nat Commun (2017) 0.75

Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer (2017) 0.75

Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ (2017) 0.75

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. Front Immunol (2017) 0.75

Matrix Mechanosensing: From Scaling Concepts in 'Omics Data to Mechanisms in the Nucleus, Regeneration, and Cancer. Annu Rev Biophys (2017) 0.75

Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75

Control of Cellular Aging, Tissue Function, and Cancer by p53 Downstream of Telomeres. Cold Spring Harb Perspect Med (2017) 0.75

Clinical importance of TERT overexpression in hepatocellular carcinoma treated with curative surgical resection in HBV endemic area. Sci Rep (2017) 0.75

The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Oncogene (2017) 0.75

Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families. J Invest Dermatol (2017) 0.75

Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. Int J Mol Sci (2017) 0.75

Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75

Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep (2017) 0.75

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42

Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76

Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52

MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95

Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood (2007) 4.36

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26

Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91

In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66

Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84

Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82

Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell (2012) 2.75

Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58

Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2009) 2.50

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42

Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27

Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res (2008) 2.14

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13

Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08

Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01

Acrodermatitis enteropathica and an overview of zinc metabolism. J Am Acad Dermatol (2006) 1.99

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98

Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98

Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96

Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. J Invest Dermatol (2013) 1.91

EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol (2008) 1.88

Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol (2011) 1.85

Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83

Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol (2003) 1.81

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81

Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78

Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78

Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J Biol Chem (2004) 1.78

Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78

Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol (2010) 1.75

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood (2008) 1.73

MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72

Dyscrasias with "undetermined significance". Arch Dermatol (2005) 1.70

A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer (2013) 1.65

Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol (2009) 1.65

Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer (2002) 1.65

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood (2011) 1.64

Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer (2007) 1.62

CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell (2005) 1.61

Cutaneous collagenous vasculopathy with generalized telangiectasia in two female patients. J Am Acad Dermatol (2010) 1.59

Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol (2008) 1.58

A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56

Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. J Invest Dermatol (2006) 1.52

WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51

Neutrophilic urticaria with systemic inflammation: a case series. JAMA Dermatol (2013) 1.50

Breast carcinoma in women age 25 years or less. Cancer (2002) 1.50

Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol (2012) 1.48

Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47

Special considerations for stage IV melanoma during pregnancy. Arch Dermatol (2005) 1.46

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46

Metastatic melanoma in association with a giant congenital melanocytic nevus in an adult: controversial CGH findings. Am J Dermatopathol (2015) 1.45

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45

The spectrum of widespread hyperpigmentations from SLN to SUL. Arch Dermatol (2009) 1.44

Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43

The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol (2008) 1.43

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood (2005) 1.41

Skin cancer prevention educational resources: just a click away? Dermatol Surg (2010) 1.39

Mohs micrographic surgery concordance between Mohs surgeons and dermatopathologists. Dermatol Surg (2013) 1.38

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer (2006) 1.38

A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg (2016) 1.37

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res (2014) 1.35

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood (2007) 1.35

Aldara activates TLR7-independent immune defence. Nat Commun (2013) 1.34

HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33

Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28

Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med (2012) 1.28

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28